PDK4 AS MARKER FOR PPARDELTA MODULATION

摘要

The present invention relates to the use of PDK4 as biomarker for PPAR delta activity, and to methods of diagnosing a disease linked to dysregulation of PPARdelta activity such as for example dyslipidemia, obesity or insulin resistance, methods of monitoring the treatment of patients suffering from a disease linked to dysregulation of PPARdelta activity, and methods of identifying compounds which modulate PPARdelta activity.